Claims for Patent: 6,417,175

Summary for Patent: 6,417,175

Title:	Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Abstract:	A novel cephem compound of the formula:wherein R1 is a phosphono group or a group convertible to a phosphono group; R2 is a hydrogen atom or a group having a linkage through a carbon atom; each of Q and X is a nitrogen atom or CH; Y is S, O or CH2; n is 0 or 1; one of R3 and R4 is a pyridinium group which may be substituted and the other is a hydrogen atom or hydrocarbon group which may be substituted, or R3 and R4 taken together may form a quaternalized nitrogen-containing heterocyclic ring which may be substituted, or its ester or its salt, which has a superior anti-bacterial activity, stability, absorbability, etc., a production thereof and a pharmaceutical composition containing it, is provided.
Inventor(s):	Tomoyasu Ishikawa, Shohei Hashiguchi, Yuji Iizawa
Assignee:	Takeda Pharmaceutical Co Ltd
Application Number:	US09/555,949
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,417,175
Patent Claims:	1. A compound of the formula: wherein R1 is a phosphono group; R2 is a hydrogen atom, an optionally substituted C1-6 alkyl group or a C3-5 cycloalkyl group; each of Q and X is a nitrogen atom or CH; Y is S; n is 0 or 1; one of R3 and R4 is a pyridinium group which may be substituted and the other is a hydrogen atom or a hydrocarbon group which may be substituted, or R3 and R4 taken together may form a quaternized nitrogen-containing heterocyclic ring which may be substituted, wherein when R3 and R4 are taken together, the group of the formula wherein R5 is an optionally substituted hydrocarbon group; or salt thereof. 2. 7β-[2(Z)-ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-3-cephem-4-carboxylate. 3. A method for producing a pharmaceutical composition comprising mixing a compound of claim 1 with a pharmaceutically acceptable carrier, diluent or bulking agent. 4. 7β-[2(Z)-ethoxyimino-2-(5-phosphonoamino 1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate or its salt. 5. A method for treating a bacterial infection which comprises administering an effective amount of a compound as claimed in claim 1 to a patient suffering from the bacterial infection. 6. A method for treating a bacterial infection which comprises administering an effective amount of a compound as claimed in claim 1 together with at least one of pharmaceutically acceptable carriers, diluents and excipients to a patient suffering from the bacterial infection. 7. A method as claimed in claim 5, wherein the bacterial infection is a MRSA infection. 8. A compound as claimed in claim 1, wherein R3 is a pyridinium group which may be substituted and R4 is a hydrogen atom. 9. A compound as claimed in claim 1, wherein Q is a nitrogen atom. 10. A compound as claimed in claim 1, wherein X is a nitrogen atom. 11. A compound as claimed in claim 1, wherein n is 0. 12. A method for treating a bacterial infection which comprises administering an effective amount of a compound as claimed in claim 4 to a patient suffering from the bacterial infection. 13. A compound as claimed in claim 1, which is 7β-[2(Z)-fluoromethoxyimino-2-(5phophonoamino-1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-3-cephem-4carboxylate or its salt. 14. A method for producing a compound as claimed in claim 1, which comprises reacting a compound of the formula: or its salt; wherein each symbol has the meaning given in claim 1; with a compound of the formula: its salt or its reactive derivative; wherein each symbol has the meaning given in claim 1. 15. A method as claimed in claim 5, wherein the compound is administered by injection. 16. A method for treating a bacterial infection which comprises administering an effective amount of a compound as claimed in claim 4 together with at least one of pharmaceutically acceptable carriers, diluents and excipients to a patient suffering from the bacterial infection. 17. A pharmaceutical composition containing the compound shown in claim 1 and at least one of pharmaceutically acceptable carriers, diluents and bulking agents. 18. A pharmaceutical composition containing the compound of claim 4 and at least one of pharmaceutically acceptable carriers, diluents and bulking agents. 19. A method for producing a pharmaceutical composition comprising mixing a compound of claim 4 with a pharmaceutically acceptable carrier, diluent or bulking agent. 20. A method as claimed in claim 12, wherein the compound is administered by injection. 21. A method as claimed in claim 12, wherein the bacterial infection is a MRSA infection.